Search Within

Advanced Practice Providers

  1. "Bone Marrow Transplant"
Formats
  1. Meeting Abstract (118)
  2. Journal Article (56)
  3. Research Letter (3)
  4. Book Section (1)
  5. Review (1)
Groups
  1. Bone Marrow Transplant (179)
  2. Center for Hematologic Malignancies (179)
  3. Department of Medicine (179)
  4. Hematologic Malignancies, Division of (179)
  5. Survivorship Research (138)
  6. Nursing (135)

More Groups

People
  1. Sergio Giralt (98)
  2. Miguel-Angel Perales (77)
  3. Gunjan Shah (68)
  4. Craig Sauter (63)
  5. Sean Devlin (60)
  6. Ann Jakubowski (43)

More People

Years
  1. 2025 (1)
  2. 2024 (6)
  3. 2023 (10)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Blood (64)
  2. Biology of Blood and Marrow Transplantation (47)
  3. Bone Marrow Transplantation (9)
  4. Journal of Clinical Oncology (7)
  5. Blood Advances (6)
  6. Transplantation and Cellular Therapy (6)

More Publications

Publishers
  1. American Society of Hematology (70)
  2. Elsevier Inc. (58)
  3. Nature Publishing Group (12)
  4. American Society of Clinical Oncology (7)
  5. Wiley Blackwell (4)
  6. American Association for Cancer Research (3)

More Publishers

Results (179)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Timing and immune status after cellular therapies predict response to COVID-19 vaccines
    Meeting Abstract

    Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Journal Article

    Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
    Journal Article

    Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Improving referrals to survivorship: A patient-driven initiative
    Meeting Abstract

    Corcoran, S.; Licciardi, F.; Weber, E.; Duggan, E.; Woodside, A.; Correa, Z.; Lachaud-Richard, M.; Kassa, A.; Jakubowski, A. A.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
    Journal Article

    Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save